Toward improved grading of malignancy in oligodendrogliomas using metabolomics

Magnetic Resonance in Medicine

Volumn 59, Issue 5, 2008, Pages 959-965

  Erb, G ^a,b   Elbayed, K ^b   Piotto, M ^b,c   Raya, J ^b   Neuville, A ^a   Mohr, M ^a   Maitrot, D ^a   Kehrli, P ^a   Namer, I J ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c Bruker Corporation   (United States)

Author keywords

Glioblastoma; High resolution magic angle spinning nuclear magnetic resonance (HRMAS NMR); Metabolics; MR spectroscopy; Oligodendroglioma

Indexed keywords

BIOPSY; GRADING; METABOLISM; METABOLITES; MULTIVARIANT ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING;

GLIOBLASTOMAS; HR-MAS NMR; METABOLICS; MR SPECTROSCOPY; OLIGODENDROGLIOMA;

MAGIC ANGLE SPINNING;

4 AMINOBUTYRIC ACID; ACETIC ACID; ALANINE; ARGININE; ASPARAGINE; ASPARTIC ACID; BIOLOGICAL MARKER; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; LEUCINE; LIPID; MALIC ACID; N ACETYLASPARTIC ACID; PROLINE; TAURINE; VALINE;

ADULT; AGED; AMINO ACID METABOLISM; ARTICLE; BRAIN BIOPSY; BRAIN HYPOXIA; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GLIOBLASTOMA; HIGH RESOLUTION MAGIC ANGLE SPINNING NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; OLIGODENDROGLIOMA; PREDICTION; PROGNOSIS; STATISTICAL ANALYSIS;

EID: 42549146585     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21486     Document Type: Article

References (30)

1. 1 Kleihues P, Cavenee WK. WHO international histopathological classification of CNS tumors. Pathology and genetics tumors of the nervous system. Lyon: IARC ; 2000. p. 55–70.
2. 2 Hoang‐Xuan K, Aguirre‐Cruz L, Mokhtari K, Marie Y, Sanson M. OLIG‐1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 2002 ; 28: 89–94.
3. 3 Burger P, Scheithauer B. Oligodendroglial neoplasms. Atlas of tumor pathology, Series 3, Fascicle 10. Washington, DC: Armed Forces Institute of Pathology ; 1994. p 107–120.
4. 4 Earnest F III, Kernohan JW, Craig WM. Oligodendrogliomas; a review of 200 cases. Arch Neurol Psychiatry 1950 ; 63: 964–976.
5. 5 Smith MT, Ludwig CL, Godfrey AD, Armbrustmacher VW. Grading of oligodendrogliomas. Cancer 1983 ; 52: 2107–2114.
6. 6 Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH. Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 1992 ; 76: 428–434.
7. 7 Daumas‐Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol 1997 ; 34: 61–78.
8. 8 Sanson M, Thillet J, Hoang‐Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004 ; 16: 607–613.
9. 9 Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994 ; 145: 1175–1190.
10. 10 Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001 ; 159: 779–786.
11. 11 Nicholson JK, Lindon JC, Holmes E. “Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999 ; 29: 1181–1189.
12. 12 Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol 2002 ; 48: 155–171.
13. 13 Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004 ; 4: 551–561.
14. 14 Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 2003 ; 7: 648–654.
15. 15 Martinez‐Bisbal MC, Marti‐Bonmati L, Piquer J, Revert A, Ferrer P, Llacer JL, Piotto M, Assemat O, Celda B. 1H and 13C HR‐MAS spectroscopy of intact biopsy samples ex vivo and in vivo 1H MRS study of human high grade gliomas. NMR Biomed 2004 ; 17: 191–205.
16. 16 Cheng LL, Chang IW, Louis DN, Gonzalez RG. Correlation of high‐resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res 1998 ; 58: 1825–1832.
17. 17 Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high‐resolution magic‐angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro Oncol 2000 ; 2: 87–95.
18. 18 Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 2005 ; 18: 371–382.
19. 19 Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000 ; 13: 129–153.
20. 20 Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 2002 ; 127: 1549–1557.
21. 21 Kell DB, Brown M, Davey HM, Dunn WB, Spasic I, Oliver SG. Metabolic footprinting and systems biology: the medium is the message. Nat Rev Microbiol 2005 ; 3: 557–565.
22. 22 Piotto M, Bourdonneau M, Furrer J, Bianco A, Raya J, Elbayed K. Destruction of magnetization during TOCSY experiments performed under magic angle spinning: effect of radial B1 inhomogeneities. J Magn Reson 2001 ; 149: 114–118.
23. 23 Elbayed K, Dillmann B, Raya J, Piotto M, Engelke F. Field modulation effects induced by sample spinning: application to high‐resolution magic angle spinning NMR. J Magn Reson 2005 ; 174: 2–26.
24. 24 Davis AL, Keeler J, Laue ED, Moskau D. Experiments for recording pure absorption heteronuclear correlation spectra using pulsed field gradients. J Magn Reson 1992 ; 98: 207–216.
25. 25 Fiehn O, Kristal B, van Ommen B, Sumner LW, Sansone SA, Taylor C, Hardy N, Kaddurah‐Daouk R. Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. OMICS 2006 ; 10: 158–163.
26. 26 Tenenhaus M. La régression PLS. Théorie et pratique. Paris: Technip ; 1998.
27. 27 Giammarile F, Cinotti LE, Jouvet A, Ramackers JM, Saint Pierre G, Thiesse P, Jouanneau E, Guyotat J, Pelissou‐Guyotat I, Setiey A, Honnorat J, Le Bars D, Frappaz D. High and low grade oligodendrogliomas (ODG): correlation of amino‐acid and glucose uptakes using PET and histological classifications. J Neurooncol 2004 ; 68: 263–274.
28. 28 Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002 ; 2: 38–47.
29. 29 Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004 ; 4: 891–899.
30. 30 Costello LC, Franklin RB. “Why do tumour cells glycolyse?”: from glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005 ; 280: 1–8.